More on PVLA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/13/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Palvella Therapeutics (NQ:PVLA)
Delayed: 157.24 +9.47 (6.41%)
Prev. Close $147.77  
Open$146.61 
52 Wk High$ 
52 Wk Low$ 
Day High$158.08 
Day Low$145.79 
P/E N/A  
EPS$ 
Volume258,072 

Friends, Peers and Foes (?): PI6, BBIO, HRMY, 0ACX, ACLX (more...)

Jul 17, 2026 04:05 PM Form 4 PALVELLA THERAPEUTICS, For: Jul 15 Filed by: Goin Kathleen
Jul 15, 2026 04:20 PM Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
Jul 14, 2026 04:49 PM Form 8-K PALVELLA THERAPEUTICS, For: Jul 14
Jul 1, 2026 04:06 PM Form 4 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
Jul 1, 2026 04:05 PM Form 3 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
Jun 30, 2026 07:37 AM Form 8-K PALVELLA THERAPEUTICS, For: Jun 29
Jun 30, 2026 07:30 AM Palvella Therapeutics adds Matt Pauls to its board of directors
Jun 30, 2026 07:30 AM Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Jun 29, 2026 07:30 AM Palvella files first NDA module for rare lymphatic malformation drug
Jun 29, 2026 07:30 AM Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
View All Articles

Entities mentioned with PVLA

View All Entities